Dermavant Sciences has submitted a supplemental new drug application to the FDA for VTMA (tapinarof) cream 1%, a treatment for atopic dermatitis (AD) in patients aged 2 years and older.

Read More> https://atopicdermatitis.pocn.com/treatment/dermavant-seeks-fda-approval-for-tapinarof-cream-in-treating-young-patients-with-atopic-dermatitis/